Development and Application of Comprehensive Intervention Techniques for Adolescent Depression

Summary

In order to realize the early identification, risk warning and comprehensive intervention of adolescent depression, this project carried out research on the diagnosis platform of adolescent depression, the construction of suicide risk warning and evaluation system, the development of interpersonal psychotherapy technology (IPT-A), and the rapid intervention technology of robotic navigation repetitive transcranial magnetic stimulation (rTMS). Through the extraction of psychological, peripheral and central biological characteristics of adolescent depression and the establishment of a diagnostic platform, combined with artificial neural network to achieve efficient and accurate identification of high risk of suicide population. Antidepressant drugs combined with psychotherapy and antidepressant drugs combined with rTMS physical therapy were used to improve the clinical effective rate and recovery rate. Finally, a comprehensive prevention and control technology suitable for hospitals, schools and families to participate in.

Conditions

• Depressive Disorder
• Adolescent

Interventions

DRUG

Escitalopram

The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression

OTHER

Interpersonal Psychotherapy for Adolescent

Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.

OTHER

Escitalopram combined with psychotherapy

The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication

OTHER

Escitalopram combined with rTMS

The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication

DRUG

Escitalopram combined with sham rTMS

The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication

Sponsors & Collaborators

• First Affiliated Hospital of Zhejiang University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

12 Years

Max Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-01-31

Primary Completion

2024-12-31

Completion

2025-06-30

Countries

• China

Study Locations